Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) EPS (Basic) (2023 - 2025)

Compass Therapeutics (CMPX) has disclosed EPS (Basic) for 3 consecutive years, with -$0.08 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) rose 27.27% to -$0.08 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.42 through Dec 2025, down 13.51% year-over-year, with the annual reading at -$0.42 for FY2025, 16.67% down from the prior year.
  • EPS (Basic) hit -$0.08 in Q4 2025 for Compass Therapeutics, roughly flat from -$0.08 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.06 in Q1 2023 to a low of -$0.14 in Q2 2025.
  • Historically, EPS (Basic) has averaged -$0.09 across 3 years, with a median of -$0.08 in 2023.
  • Biggest YoY gain for EPS (Basic) was 27.27% in 2025; the steepest drop was 50.0% in 2025.
  • Year by year, EPS (Basic) stood at -$0.1 in 2023, then decreased by 10.0% to -$0.11 in 2024, then rose by 27.27% to -$0.08 in 2025.
  • Business Quant data shows EPS (Basic) for CMPX at -$0.08 in Q4 2025, -$0.08 in Q3 2025, and -$0.14 in Q2 2025.